Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.37 |
| ▸ | CDC25B | P30305 | 5/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579768 | 0.92 | TACR2 (0.43) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL11997783 | 0.84 | IP6K1 (0.33) | TACR2 | |
| SCHEMBL264765 | 0.81 | HTR1A (0.42) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL264654 | 0.79 | TACR2 (0.32) | HTR1ATACR2NT5EBCHEACHE | |
| SCHEMBL2101954 | 0.78 | TACR2 (0.40) | HTR1ATACR2NT5EBCHEPTPN1 | |
| SCHEMBL22579769 | 0.77 | HTR1A (0.39) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL24557949 | 0.77 | HTR1A (0.42) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL22569935 | 0.77 | PDE2A (0.45) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL20214810 | 0.74 | HTR1A (0.43) | HTR1ATACR2NT5ECA1CA2 | |
| SCHEMBL24557945 | 0.74 | HTR1A (0.39) | HTR1ATACR2NT5ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3956341-A1 | CD73 INHIBITORS | Bioardis LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | HTR1A 4285/4885TACR2 4788/4885NT5E 170/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | HTR1A 2118/4885TACR2 2520/4885NT5E 8/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | HTR1A 4620/4885TACR2 1850/4885NT5E 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.